CL2024000151A1 - Proteínas actrii y usos de las mismas. - Google Patents

Proteínas actrii y usos de las mismas.

Info

Publication number
CL2024000151A1
CL2024000151A1 CL2024000151A CL2024000151A CL2024000151A1 CL 2024000151 A1 CL2024000151 A1 CL 2024000151A1 CL 2024000151 A CL2024000151 A CL 2024000151A CL 2024000151 A CL2024000151 A CL 2024000151A CL 2024000151 A1 CL2024000151 A1 CL 2024000151A1
Authority
CL
Chile
Prior art keywords
telangiectasia
risk
effective amount
therapeutically effective
patient receiving
Prior art date
Application number
CL2024000151A
Other languages
English (en)
Spanish (es)
Inventor
De Oliveira Pena Janethe
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CL2024000151A1 publication Critical patent/CL2024000151A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CL2024000151A 2021-07-19 2024-01-17 Proteínas actrii y usos de las mismas. CL2024000151A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19

Publications (1)

Publication Number Publication Date
CL2024000151A1 true CL2024000151A1 (es) 2024-08-09

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000151A CL2024000151A1 (es) 2021-07-19 2024-01-17 Proteínas actrii y usos de las mismas.

Country Status (18)

Country Link
US (1) US20240327494A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526820A (cg-RX-API-DMAC7.html)
KR (1) KR20240049857A (cg-RX-API-DMAC7.html)
CN (1) CN117957014A (cg-RX-API-DMAC7.html)
AU (1) AU2022316103A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225613A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000151A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024001551A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240061A (cg-RX-API-DMAC7.html)
DO (2) DOP2024000016A (cg-RX-API-DMAC7.html)
EC (1) ECSP24012819A (cg-RX-API-DMAC7.html)
GE (1) GEP20267899B (cg-RX-API-DMAC7.html)
IL (1) IL310141A (cg-RX-API-DMAC7.html)
JO (1) JOP20240010A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000829A (cg-RX-API-DMAC7.html)
PE (1) PE20240777A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023003815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI745271B (zh) * 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
WO2016146573A1 (en) * 2015-03-13 2016-09-22 Repoceuticals Aps Melatonin for preventing and treating radiation cystitis
JP7072507B2 (ja) * 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
PL4218804T3 (pl) * 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
AU2017296040C1 (en) * 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension

Also Published As

Publication number Publication date
DOP2024000016A (es) 2024-06-16
GEAP202416461A (en) 2024-04-25
CO2024001551A2 (es) 2024-03-07
AU2022316103A1 (en) 2024-02-08
US20240327494A1 (en) 2024-10-03
MX2024000829A (es) 2024-04-12
WO2023003815A1 (en) 2023-01-26
EP4373577A4 (en) 2025-05-14
CR20240061A (es) 2024-05-02
CN117957014A (zh) 2024-04-30
JP2024526820A (ja) 2024-07-19
DOP2026000113A (es) 2026-07-15
WO2023003815A9 (en) 2023-05-11
IL310141A (en) 2024-03-01
JOP20240010A1 (ar) 2024-01-18
ECSP24012819A (es) 2024-03-01
GEP20267899B (en) 2026-06-10
CA3225613A1 (en) 2023-01-26
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
EP4373577A1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CO2024001551A2 (es) Proteínas actrii y usos de las mismas
AR111455A1 (es) Formulación estable de anticuerpo
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MX389598B (es) Inhibidores bicíclicos condensados de la interacción de menina-mll.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
BR112021020975A2 (pt) Composições e métodos relacionados com pacotes de mensageiros de plantas
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
CL2022001185A1 (es) Derivados terapéuticos de interleucina-22
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
PE20190171A1 (es) Anticuerpos de union a trombina y usos del mismo
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
CO2017007316A2 (es) Formulación farmacéutica
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
PE20170287A1 (es) Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
MX2021005910A (es) Formulacion de proteina de alta concentracion.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
UY36650A (es) Polipéptidos dirigidos a la fusión de vih
AR104721A1 (es) Fragmento fab anti-ngf humano
DOP2025000170A (es) Proteínas de fusión fc de il-12